Aspectos Clínicos y Epidemiológicos del VIH y Condiciones Asociadas

Podzamczer, D; Tiraboschi, JM; Mallolas, J; Curto, J; Cardenes, MA; Casas, E; Castro, A; Echevarria, S; Leal, M; de Quiros, JCLB; Moreno, S; Puig, T; Ribera, E; Villalonga, C; Gomez-Sirvent, JL; Garcia-Henarejos, JA; Lopez-Aldeguer, J; Barrufet, P; Force, L; Santos, I; Sanz, J.

Long-Term Benefits of Nevirapine-Containing Regimens: Multicenter Study with 506 Patients, Followed-Up a Median of 9 Years

CURRENT HIV RESEARCH. 2012; 10(6): 513-520 Nº de citas: 5 [doi:10.2174/157016212802429820]

Berenguer, J; Rodriguez, E; Miralles, P; Von Wichmann, MA; Lopez-Aldeguer, J; Mallolas, J; Galindo, MJ; Van Den Eynde, E; Tellez, MJ; Quereda, C; Jou, A; Sanz, J; Barros, C; Santos, I; Pulido, F; Guardiola, JM; Ortega, E; Rubio, R; Jusdado, JJ; Montes, ML; Gaspar, G; Esteban, H; Bellon, JM; Gonzalez-Garcia, J.

Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus

CLINICAL INFECTIOUS DISEASES. 2012; 55(5): 728-736 Nº de citas: 149 [doi:10.1093/cid/cis500]

Miro, JM; Montejo, M; Castells, L; Rafecas, A; Moreno, S; Aguero, F; Abradelo, M; Miralles, P; Torre-Cisneros, J; Pedreira, JD; Cordero, E; de la Rosa, G; Moyano, B; Moreno, A; Perez, I; Rimola, A.

Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study

AMERICAN JOURNAL OF TRANSPLANTATION. 2012; 12(7): 1866-1876 Nº de citas: 121 [doi:10.1111/j.1600-6143.2012.04028.x]

Berenguer, J; Pedrol, PD; Polo, R; Aguirrebengoa, K; Estrada, V; Rodero, FG; Knobel, H; Llibre, JM; Miralles, C; Miro, JM; Rivero, A; Santos, J; Tuset, M; Antela, A; Asensi, V; Arribas, JR; Blanco, JR; Boix, V; Martinez, E; Garcia, F; Gatell, JM; Mallolas, J; Moreno, S; Palacios, R; Elias, MJP; Pineda, JA; Vidal, F; Aldeguer, JL.

Executive summary. Consensus document of GESIDA and SPNS (Spanish Secretariat for the National Plan on AIDS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2012; 30(6): 315-324 Nº de citas: 2 [doi:10.1016/j.eimc.2012.03.007]

Blasco, AJ; Arribas, JR; Boix, V; Clotet, B; Domingo, P; Gonzalez-Garcia, J; Knobel, H; Lopez, JC; Llibre, JM; Lozano, F; Miro, JM; Podzamczer, D; Santamaria, JM; Tuset, M; Zamora, L; Lazaro, P; Gatell, JM.

Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National plan for AIDS for the initial antiretroviral therapy in adult human Immunodeficiency virus (HIV) infected patients in 2012

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2012; 30(6): 283-293 Nº de citas: 14 [doi:10.1016/j.eimc.2012.02.016]

Guzman-Fulgencio, M; Jimenez, JL; Berenguer, J; Fernandez-Rodriguez, A; Lopez, JC; Cosin, J; Miralles, P; Micheloud, D; Munoz-Fernandez, MA; Resino, S.

Plasma IL-6 and IL-9 predict the failure of interferon-alpha plus ribavirin therapy in HIV/HCV-coinfected patients

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2012; 67(5): 1238-1245 Nº de citas: 29 [doi:10.1093/jac/dkr595]

Monge, S; del Romero, J; Rodriguez, C; de Mendoza, C; de Gorgolas, M; Cosin, J; Dronda, F; Perez-Cecilia, E; Pena, JM; Santos, I; Rubio, R; del Amo, J.

Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986-2009)

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2012; 30(3): 117-123 Nº de citas: 3 [doi:10.1016/j.eimc.2011.07.016]

Yebra, G; de Mulder, M; Martin, L; Rodriguez, C; Labarga, P; Viciana, I; Berenguer, J; Aleman, MR; Pineda, JA; Garcia, F; Holguin, A.

Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naive HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses

JOURNAL OF CLINICAL MICROBIOLOGY. 2012; 50(2): 407-413 Nº de citas: 36 [doi:10.1128/JCM.05798-11]

Sobrino-Vegas, P; Rodriguez-Urrego, J; Berenguer, J; Caro-Murillo, AM; Blanco, JR; Viciana, P; Moreno, S; Bernardino, I; del Amo, J.

Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care

ANTIVIRAL THERAPY. 2012; 17(1): 1-8 Nº de citas: 44 [doi:10.3851/IMP1939]

Berenguer, J; Fernandez-Rodriguez, A; Jimenez-Sousa, MA; Cosin, J; Zarate, P; Micheloud, D; Lopez, JC; Miralles, P; Catalan, P; Resino, S.

High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients

CYTOKINE. 2012; 57(1): 25-29 Nº de citas: 21 [doi:10.1016/j.cyto.2011.10.020]

Micheloud, D; Berenguer, J; Guzman-Fulgencio, M; Campos, Y; Garcia-Alvarez, M; Catalan, P; Cosin, J; Miralles, P; Lopez, JC; Resino, S.

European Mitochondrial DNA Haplogroups and Metabolic Disorders in HIV/HCV-Coinfected Patients on Highly Active Antiretroviral Therapy

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2011; 58(4): 371-378 Nº de citas: 21 [doi:10.1097/QAI.0b013e31822d2629]

Blasco, AJ; Arribas, JR; Clotet, B; Domingo, P; Gonzalez-Garcia, J; Lopez-Bernaldo, JC; Llibre, JM; Lozano, F; Podzamczer, D; Santamaria, JM; Tuset, M; Zamora, L; Lazaro, P; Gatell, JM.

Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2011; 29(10): 721-730 Nº de citas: 11 [doi:10.1016/j.eimc.2011.08.003]

Berenguer, J; von Wichmann, MA; Quereda, C; Miralles, P; Mallolas, J; Lopez-Aldeguer, J; Alvarez-Pellicer, J; De Miguel, J; Crespo, M; Guardiola, JM; Tellez, MJ; Galindo, MJ; Arponen, S; Barquilla, E; Bellon, JM; Gonzalez-Garcia, J.

Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2011; 66(12): 2843-2849 Nº de citas: 13 [doi:10.1093/jac/dkr362]

Sobrino-Vegas, P; Gutierrez, F; Berenguer, J; Labarga, P; Garcia, F; Alejos-Ferreras, B; Munoz, MA; Moreno, S; del Amo, J.

The cohort of the spanish hiv research network (coris) and its associated biobank; organizational issues, main findings and losses to follow-up

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2011; 29(9): 645-653 Nº de citas: 119 [doi:10.1016/j.eimc.2011.06.002]

Mugavero, MJ; May, M; Ribaudo, HJ; Gulick, RM; Riddler, SA; Haubrich, R; Napravnik, S; Abgrall, S; Phillips, A; Harris, R; Gill, MJ; de Wolf, F; Hogg, R; Gunthard, HF; Chene, G; Monforte, AD; Guest, JL; Smith, C; Murillas, J; Berenguer, J; Wyen, C; Domingo, P; Kitahata, MM; Sterne, JAC; Saag, MS.

Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2011; 58(3): 253-260 Nº de citas: 19 [doi:10.1097/QAI.0b013e318230372e]

Gomez, CE; Najera, JL; Perdiguero, B; Garcia-Arriaza, J; Sorzano, COS; Jimenez, V; Gonzalez-Sanz, R; Jimenez, JL; Munoz-Fernandez, MA; de Quiros, JCLB; Guardo, AC; Garcia, F; Gatell, JM; Plana, M; Esteban, M.

The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens

JOURNAL OF VIROLOGY. 2011; 85(21): 11468-11478 Nº de citas: 68 [doi:10.1128/JVI.05165-11]

Resino, S; Asensio, C; Bellon, JM; Carmona, R; Miralles, P; Lopez, JC; Cosin, J; Alvarez, E; Berenguer, J.

Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients: A validation study

JOURNAL OF INFECTION. 2011; 63(5): 402-405 Nº de citas: 18 [doi:10.1016/j.jinf.2011.07.017]

Garcia, F; de Quiros, JCLB; Gomez, CE; Perdiguero, B; Najera, JL; Jimenez, V; Garcia-Arriaza, J; Guardo, AC; Perez, I; Diaz-Brito, V; Conde, MS; Gonzalez, N; Alvarez, A; Alcami, J; Jimenez, JL; Pich, J; Arnaiz, JA; Maleno, MJ; Leon, A; Munoz-Fernandez, MA; Liljestrom, P; Weber, J; Pantaleo, G; Gatell, JM; Plana, M; Esteban, M.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

VACCINE. 2011; 29(46): 8309-8316 Nº de citas: 81 [doi:10.1016/j.vaccine.2011.08.098]